Strategic Partners A/S FCF/Debt

What does Strategic Partners A/S do? Orphazyme A/S develops treatments for rare genetic disorders, focusing on lysosomal storage diseases and protein aggregation diseases. The company's main product, arimoclomol, works by stimulating heat shock proteins to help misfolded proteins either refold correctly or be removed via lysosomes. Orphazyme collaborates with academic institutions in Europe and the United States to advance its preclinical development efforts. The company generates revenue through partnerships and collaborations with academic institutions for the development of its therapies. These partnerships support the preclinical research phase of arimoclomol, which targets approximately 50 genetic disorders known as lysosomal storage diseases. Orphazyme's focus remains on advancing its pipeline of treatments for life-threatening and debilitating rare diseases. Orphazyme A/S serves the medical research and pharmaceutical sectors by providing innovative therapeutic approaches for rare diseases. Its target market includes patients with lysosomal storage diseases and protein aggregation disorders, who face significant health challenges due to genetic deficiencies. The company's work aims to address unmet medical needs in these rare disease areas. Strategic Partners A/S is one of the most popular companies on Eulerpool.